


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 307/93, 493/04, A61K 31/34, 31/495, 31/535, 31/445	A1	(11) International Publication Number: WO 99/19317 (43) International Publication Date: 22 April 1999 (22.04.99)
(21) International Application Number: PCT/EP98/06352 (22) International Filing Date: 6 October 1998 (06.10.98) (30) Priority Data: 97203154.6 10 October 1997 (10.10.97) EP (71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): ANDRÉS-GIL, José Ignacio [ES/ES]; Vesubiana, 22, Getafe-Sector 3, E-28905 Madrid (ES). FERNÁNDEZ-GADEA, Francisco Javier [ES/ES]; Sagra, 20, Cerro De Las Perdices (Bargas), E-45593 Toledo (ES). GIL-LOPETEGUI, Pilar [ES/ES]; Santa Ursula, 10, E-45002 Toledo (ES). DÍAZ-MARTÍNEZ, Adolfo [ES/ES]; Avenida España, 43, 2 D Getafe, E-28903 Madrid (ES).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: HALOGEN SUBSTITUTED TETRACYCLIC TETRAHYDROFURAN DERIVATIVES

(I)

(57) Abstract

This invention concerns the compounds of formula (I), the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein *n* is zero, 1, 2, 3, 4, 5 or 6; *X* is CH₂ or O; *R*¹ and *R*² each independently are hydrogen, C₁-alkyl, C₁-alkylcarbonyl, halomethylcarbonyl or C₁-alkyl substituted with hydroxy, C₁-alkyloxy, carboxyl, C₁-alkylcarbonyloxy, C₁-alkyloxycarbonyl or aryl; or *R*¹ and *R*² taken together with the nitrogen atom to which they are attached may form a morpholinyl ring or an optionally substituted heterocycle; *R*³ and *R*⁴ are both halogen; or *R*³ is halogen and *R*⁴ is hydrogen; or *R*³ is hydrogen and *R*⁴ is halogen; and aryl is phenyl or phenyl substituted with 1, 2 or 3 substituents selected from halo, hydroxy, C₁-alkyl and halomethyl. The compounds of formula (I) may be used as therapeutic agents.